GPRC5D CART therapy
/ Hadassah Medical Organization
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 15, 2026
Phase 1a/b Study of GPRC5D CART Therapy in Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis
(clinicaltrials.gov)
- P1 | N=160 | Not yet recruiting | Sponsor: Hadassah Medical Organization
New P1 trial • Amyloidosis • Hematological Malignancies • Multiple Myeloma • Oncology
1 to 1
Of
1
Go to page
1